Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 24, Number 3—March 2018

Ceftriaxone-Resistant Neisseria gonorrhoeae, Canada, 2017

Cite This Article

To the Editor: I read with great interest the report by Lefebvre et al. about a Neisseria gonorrhoeae isolate identified in Canada demonstrating a ceftriaxone MIC of 1 mg/L (1). The authors note: “As of October 15, 2017, only 5 ceftriaxone-resistant Neisseria gonorrhoeae isolates had been reported worldwide (MIC range 0.5–2 mg/L).” The authors cite published reports from Spain, Japan, Australia, and France.

I would like to clarify that additional N. gonorrhoeae isolates have been identified with ceftriaxone MICs >0.5 mg/L. Since 1987, as part of the Gonococcal Isolate Surveillance Project, the Centers for Disease Control and Prevention has been testing N. gonorrhoeae isolates for ceftriaxone susceptibility. During 1987–2016, the Centers for Disease Control and Prevention identified and reported 5 isolates with ceftriaxone MICs of 0.5 mg/L in the United States. These isolates were found in San Diego, California (1987); Cincinnati, Ohio (1992 and 1993); Philadelphia, Pennsylvania (1997); and most recently, Oklahoma City, Oklahoma (2012) (2). Therefore, although the number of N. gonorrhoeae isolates with ceftriaxone MICs >0.5 mg/L identified globally to date has been small, these Gonococcal Isolate Surveillance Project findings should be acknowledged. Continued and enhanced global surveillance of gonococcal isolates for antimicrobial susceptibility testing is imperative.


Alan R. KatzComments to Author 

Author affiliation: University of Hawaii, Honolulu, Hawaii, USA



  1. Lefebvre  B, Martin  I, Demczuk  W, Deshaies  L, Michaud  S, Labbé  AC, et al. Ceftriaxone-Resistant Neisseria gonorrhoeae, Canada, 2017. Emerg Infect Dis. 2018;24:3813. DOIPubMed
  2. Centers for Disease Control and Prevention. Sexually transmitted diseases surveillance 2016 [cited 2017 Nov 19].


Cite This Article

DOI: 10.3201/eid2403.171892

Related Links


Table of Contents – Volume 24, Number 3—March 2018


Please use the form below to submit correspondence to the authors or contact them at the following address:

Alan R. Katz, University of Hawaii at Manoa, Office of Public Health Studies, Biomedical Sciences Bldg, Rm D104M, 1960 East-West Rd, Honolulu, HI 96822, USA

Send To

character(s) remaining.

Comment submitted successfully, thank you for your feedback.


Page created: February 23, 2018
Page updated: February 23, 2018
Page reviewed: February 23, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.